High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
74.32M
+50.88%
--
--
93.98M
+40.63%
--
--
72.40M
+51.37%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Harrow, Inc. (HROW) for FY2025, with the revenue forecasts being adjusted by 1.39% over the past three months. During the same period, the stock price has changed by 45.27%.
Revenue Estimates for FY2025
Revise Upward
+1.39%
In Past 3 Month
Stock Price
Go Up
+45.27%
In Past 3 Month
8 Analyst Rating
0Wall Street analysts forecast HROW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HROW is 54.60 USD with a low forecast of 33.00 USD and a high forecast of 76.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
0Current: 36.500
Low
33.00
Averages
54.60
High
76.00
0Current: 36.500
Low
33.00
Averages
54.60
High
76.00
Cantor Fitzgerald
NULL -> Overweight
initiated
$76
2025-07-11
Reason
Cantor Fitzgerald
Price Target
$76
2025-07-11
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Harrow with an Overweight rating and $76 price target.
Cantor Fitzgerald
Steve Seedhouse
Overweight
initiated
$76
2025-07-11
Reason
Cantor Fitzgerald
Steve Seedhouse
Price Target
$76
2025-07-11
initiated
Overweight
Reason
Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Harrow with an Overweight rating and $76 price target. The firm cites a path to strong growth and profitability, and believes Harrow is on a path to become the leading diversified U.S. ophthalmology company, the analyst tells investors in a research note. Cantor says Harrow has a \"very good\" setup for Q2, and guidance for 2025 is potentially conservative.
BTIG
Buy
initiated
$62
2025-06-11
Reason
BTIG
Price Target
$62
2025-06-11
initiated
Buy
Reason
BTIG initiated coverage of Harrow with a Buy rating and $62 price target. The company has 16 important products, most of which it considered to be best in class, and the key to a Harrow investment is that the company continues to both drive growth of existing products and to acquire new products where the Harrow footprint is a powerful advantage to commercialization, the analyst tells investors in a research note. BTIG adds that it expects Harrow's near-term and ongoing updates on the progress of these approaches and signs that the company is on track to meet 2025 revenue guidance of $280M to be the key catalysts for the stock over the remainder of 2025.
William Blair
Lachlan Hanbury-Brown
Outperform
initiated
$63
2025-06-10
Reason
William Blair
Lachlan Hanbury-Brown
Price Target
$63
2025-06-10
initiated
Outperform
Reason
William Blair analyst Lachlan Hanbury-Brown initiated coverage of Harrow with an Outperform rating and $63 fair value estimate. Harrow is a commercial-stage pharmaceutical company focused exclusively on ophthalmology, the analyst tells investors in a research note. The firm says the company started out as a compounding pharmacy business but has expanded into branded pharmaceuticals by acquiring a large portfolio of branded therapies that offer an attractive growth and margin profile. The recent launch of Harrow's access and affordability program, Vevye Access for All, "is rapidly accelerating growth," contends Blair. The firm believes the company is still early in the adoption for the product and sees the recent reintroduction of Triesence as a complementary growth driver in this segment.
H.C. Wainwright
Yi Chen
Buy
maintain
$57 -> $60
2025-05-12
Reason
H.C. Wainwright
Yi Chen
Price Target
$57 -> $60
2025-05-12
maintain
Buy
Reason
H.C. Wainwright analyst Yi Chen raised the firm's price target on Harrow to $60 from $57 and keeps a Buy rating on the shares following the Q1 report. Management reiterated 2025 revenue target of over $280M, which would represent a growth rate of over 40% in 2025, the analyst tells investors in a research note.
Craig-Hallum
Chase Knickerbocker
Buy
downgrade
$58 -> $54
2025-05-12
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$58 -> $54
2025-05-12
downgrade
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker lowered the firm's price target on Harrow to $54 from $58 and keeps a Buy rating on the shares following the Q1 earnings miss. Revenue was $47.8M vs Street estimates of $57.0M, and adjusted EBITDA was ($1.9M) vs $11.9M. The quarter reflected complex destocking headwinds, and GTN headwinds, the firm notes. Iheezo underperformed, as distributor inventory unwinding was much greater than expected. Anterior segment products were also affected by some prior under accruals. The compounding business came in slightly below expectations as well. However, Vevye was a standout, exceeding internal expectations and expected to contribute about $100M for the year, Craig-Hallum points out.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Harrow Inc (HROW.O) is 37.94, compared to its 5-year average forward P/E of 66.19. For a more detailed relative valuation and DCF analysis to assess Harrow Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
66.19
Current PE
37.94
Overvalued PE
338.75
Undervalued PE
-206.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
15.13
Current EV/EBITDA
14.36
Overvalued EV/EBITDA
20.88
Undervalued EV/EBITDA
9.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
3.25
Current PS
3.87
Overvalued PS
4.42
Undervalued PS
2.07
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 135.73% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 135.73% over the last month.
Sold
Bought
HROW News & Events
Events Timeline
(ET)
2025-07-17
07:09:33
Harrow enters commercialization agreement with Samsung Bioepis for biosimilars
2025-07-11 (ET)
2025-07-11
08:52:56
Video: Capricor plunges after CRL, Performance Foods up after seeing interest
2025-06-09 (ET)
2025-06-09
07:10:50
Harrow acquires U.S. commercial rights to BYQLOVI 0.05% from Formosa
Sign Up For More Events
Sign Up For More Events
News
Preview
9.5
08-12SeekingAlphaPinnedHarrow Health Non-GAAP EPS of $0.24 beats by $0.20, revenue of $63.7M misses by $2.33M
Preview
7.0
08-13GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Preview
8.0
08-13NASDAQ.COMNotable Tuesday Option Activity: CIVI, HROW, MRNA
Sign Up For More News
People Also Watch
FAQ
What is Harrow Inc (HROW) stock price today?
What is Harrow Inc (HROW)'s business?
What is the price predicton of HROW Stock?
What is Harrow Inc (HROW)'s revenue for the last quarter?
What is Harrow Inc (HROW)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Harrow Inc (HROW)'s fundamentals?
How many employees does Harrow Inc (HROW). have?